



## Announcement Summary

**Entity name**

TELIX PHARMACEUTICALS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Thursday March 12, 2026

**The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

Shares issued under the Telix Employee Share/Stock Purchase Plans. Refer to Equity Incentive Plan Rules at <https://ir.telixpharma.com/governance/documents-charters> for Australian employee participants and Employee Stock Purchase Plan Rules within Telix 2024 and 2025 Annual Report (on Form 20-F) at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <https://ir.telixpharma.com/financial-information/annual-reports> for US employee participants

**Total number of +securities to be quoted**

<b>ASX +security code</b>	<b>Security description</b>	<b>Number of +securities to be quoted</b>	<b>Issue date</b>
TLX	ORDINARY FULLY PAID	50,782	12/03/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of entity**

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

**1.2 Registered number type**

ACN

**Registration number**

616620369

**1.3 ASX issuer code**

TLX

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

12/3/2026



Part 2 - Type of Issue

---

**2.1 The +securities to be quoted are:**

Other

**Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.**

**2.2 The +class of +securities to be quoted is:**

Additional +securities in a class that is already quoted on ASX ("existing class")

**2.3c Have these +securities been offered under a +disclosure document or +PDS?**

No

**2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B**

Shares issued under the Telix Employee Share/Stock Purchase Plans. Refer to Equity Incentive Plan Rules at <https://ir.telixpharma.com/governance/documents-charters> for Australian employee participants and Employee Stock Purchase Plan Rules within Telix 2024 and 2025 Annual Report (on Form 20-F) at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <https://ir.telixpharma.com/financial-information/annual-reports> for US employee participants

**2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:**

Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

TLX : ORDINARY FULLY PAID

**Issue date**

12/3/2026

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

Issue details

**Number of +securities to be quoted**

32,611

**Are the +securities being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?      What is the issue price per +security?**

AUD - Australian Dollar

AUD 8.29600000

**Any other information the entity wishes to provide about the +securities to be quoted**

**The purpose(s) for which the entity is issuing the securities**

Other

**Please provide additional details**

32,611 ordinary shares issued to Australian employees under the Telix Employee Share Purchase Plan. Refer to Equity Incentive Plan Rules at <https://ir.telixpharma.com/governance/documents-charters>. Shares issued will be restricted from trade or transfer until September 2027.

**Additional +securities to be quoted in an existing class**

**ASX +security code and description**

TLX : ORDINARY FULLY PAID

**Issue date**

12/3/2026

**Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes



Issue details

---

**Number of +securities to be quoted**

18,171

**Are the +securities being issued for a cash consideration?**

Yes

**In what currency is the cash consideration being paid?      What is the issue price per +security?**

USD - US Dollar

USD 5.99250000

**Any other information the entity wishes to provide about the +securities to be quoted**

**The purpose(s) for which the entity is issuing the securities**

Other

**Please provide additional details**

18,171 shares issued which will be distributed to the Telix US depository bank and allocated to US employees as American Depository Shares (ADS) under the Telix Employee Stock Purchase Plan (ESPP). Refer to ESPP Rules within Telix 2024 and 2025 Annual Report (on Form 20-F) at <https://ir.telixpharma.com/filings/sec-filings> and 2025 AGM Notice of Meeting at <https://ir.telixpharma.com/financial-information/annual-reports>. ADS allocated will be restricted from trade or transfer until September 2027.



## Part 4 - Issued capital following quotation

**Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:**

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLX : ORDINARY FULLY PAID	338,891,048

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	9,965,235
TLXAP : SHARE RIGHTS	1,220,004
TLXAO : SHARE APPRECIATION RIGHTS	15,239,149
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	208,397
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAU : DEFERRED SHARE RIGHTS EX-US 2024	10,561
TLXAV : DEFERRED SHARE RIGHTS US 2024	1,957
TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 2025	4,352,537
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

---

**5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?**

Yes

**5.1a Select the number of the applicable exception in Listing Rule 7.2**

13